Merrill keeps Human Genome at buy

Human Genome Sciences, Inc.: was maintained by Merrill Lynch analyst Hari Sambasivam at buy after the company reported in-line third-quarter results. Total revenues were $6.7 million and total expenses were $65.7 million. The analyst estimated total revenues of $4.7 million and total expenses of $64.0 million. In the past two years, Human Genome Sciences has made significant progress in reducing its cash burn and advancing products into phase 3, according to Sambasivam. Shares of the Rockville, Md.-based biopharmaceutical company were down $1.12, or 8.10%, at $12.71. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.